EXOTECT is focused on developing a rational approach towards discovery of therapeutic candidates for asthmatics and patients of other respiratory diseases where mucus overproduction is a feature.Asthma and COPD can be controlled with proper therapeutic interventions but there are still 5-10% of patients that remain refractory. Refractory patients accounted for nearly 25,000 deaths in just asthma alone. Currently the global asthma market is expected to reach 23.1 billion by 2023. However, treatment regiments are still poor for those with refractory disease. Currently, the market is dominated by corticosteroids and bronchodilators that treat symptoms rather than the underlying cause. The prescription of a handful of drugs and the prevalence of refractory patients highlights the need for new therapeutic interventions. Mucus hyperproduction in asthma is an important component of the mortality and morbidity related to this disease. An effective therapy for this is an urgent clinical need. As of now, no effective therapies exist that tackles this aspect of asthma, despite significant advances in management of other aspects of the disease like airway hyperreactivity and inflammation.
IN THE NEWS
Xconomy, November 2015